BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (BBIO) has announced new equity grants approved by its compensation committee on April 9, 2025. The grants consist of restricted stock units totaling 77,652 shares, awarded to 20 new employees.
The vesting schedule specifies that one-fourth of each employee's shares will vest on May 16, 2026, followed by quarterly vesting of one-twelfth of the remaining shares, contingent on continued employment. These inducement grants were made under the company's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma (BBIO) ha annunciato nuove concessioni di capitale approvate dal suo comitato per la compensazione il 9 aprile 2025. Le concessioni consistono in unità di azioni vincolate per un totale di 77.652 azioni, assegnate a 20 nuovi dipendenti.
Il piano di maturazione specifica che un quarto delle azioni di ciascun dipendente maturerà il 16 maggio 2026, seguito da una maturazione trimestrale di un dodicesimo delle azioni rimanenti, a condizione di un impiego continuativo. Queste concessioni di indennità sono state effettuate nell'ambito del Piano di Indennità Azionaria 2019 Modificato e Ripristinato dell'azienda, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO) ha anunciado nuevas concesiones de capital aprobadas por su comité de compensación el 9 de abril de 2025. Las concesiones consisten en unidades de acciones restringidas que totalizan 77,652 acciones, otorgadas a 20 nuevos empleados.
El calendario de adquisición especifica que una cuarta parte de las acciones de cada empleado se adquirirán el 16 de mayo de 2026, seguido de una adquisición trimestral de un duodécimo de las acciones restantes, condicionado a la continuidad del empleo. Estas concesiones de inducción se realizaron bajo el Plan de Inducción de Capital Modificado y Restablecido de 2019 de la empresa, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO)는 2025년 4월 9일 보상위원회에서 승인한 신규 주식 보상을 발표했습니다. 이 보상은 20명의 신규 직원에게 수여된 총 77,652주의 제한 주식 단위로 구성됩니다.
주식의 취득 일정은 각 직원의 주식 중 1/4이 2026년 5월 16일에 취득되며, 이후 나머지 주식의 1/12이 분기별로 취득되도록 규정되어 있으며, 이는 지속적인 고용에 따라 달라집니다. 이러한 유도 보상은 회사의 2019년 수정 및 재정립된 유도 주식 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 시행됩니다.
BridgeBio Pharma (BBIO) a annoncé de nouvelles attributions d'actions approuvées par son comité de rémunération le 9 avril 2025. Les attributions consistent en des unités d'actions restreintes totalisant 77 652 actions, attribuées à 20 nouveaux employés.
Le calendrier d'acquisition précise qu'un quart des actions de chaque employé sera acquis le 16 mai 2026, suivi d'une acquisition trimestrielle d'un douzième des actions restantes, sous réserve d'un emploi continu. Ces attributions d'incitation ont été effectuées dans le cadre du Plan d'Attribution d'Actions Modifié et Révisé de 2019 de l'entreprise, conformément à la règle de cotation Nasdaq 5635(c)(4).
BridgeBio Pharma (BBIO) hat am 9. April 2025 neue Aktienzuteilungen angekündigt, die von seinem Vergütungsausschuss genehmigt wurden. Die Zuteilungen bestehen aus beschränkten Aktieneinheiten in Höhe von insgesamt 77.652 Aktien, die an 20 neue Mitarbeiter vergeben werden.
Der Vesting-Zeitplan legt fest, dass ein Viertel der Aktien jedes Mitarbeiters am 16. Mai 2026 fällig wird, gefolgt von einer vierteljährlichen Vesting von einem Zwölftel der verbleibenden Aktien, abhängig von einer fortdauernden Beschäftigung. Diese Anreizzuteilungen wurden im Rahmen des Änderten und Wiederhergestellten Aktienanreizplans 2019 des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- Successful recruitment of 20 new employees indicates company growth
- Structured vesting schedule helps retain talent over long-term
- 77,652 new shares will cause minor shareholder dilution
PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on April 9, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 20 new employees in restricted stock units for an aggregate of 77,652 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
FAQ
How many shares were granted in BridgeBio's (BBIO) April 2025 inducement grants?
What is the vesting schedule for BBIO's April 2025 restricted stock units?
When did BridgeBio last update its Inducement Equity Plan?
How many new employees received BBIO stock grants in April 2025?
